CN Bio Innovations Secures $9 Million in Funding
CN Bio Innovations has raised $9 million (£6.9 million) in investment funding that will be used to support commercial development and strengthen market position in the United States
According to a March 2, 2020 press release, CN Bio Innovations has raised $9 million (£6.9 million) in investment funding that will be used to support commercial development and strengthen market position in the United States.
Additionally, the company reported that the funding will be used to expand its operations across Europe and drive sales of its products and services including the PhysioMimix platform. Further to the investment news, the company has also revealed that it is relocating and expanding its headquarters to the Cambridge Science Park in the United Kingdom.
“This investment will enable us to focus on the delivery of our business strategy and the company’s commercial growth, while ensuring that we remain at the forefront of the organ-on-chip technologies field,” said Dr. David Hughes, CEO, CN Bio Innovations, in the press release. “We are delighted to have secured this investment from both new and existing investors, which reflects both the potential of our technology and products, as well as the unrivalled experience and capabilities of our team.”
Source: CN Bio
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
